RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
固有淋巴样细胞：癌症治疗的潜在靶点
英文原题：Innate lymphoid cells: potential targets for cancer therapeutics.
查看英文原题
Innate lymphoid cells: potential targets for cancer therapeutics.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
固有淋巴样细胞（ILC）包括多种不同的亚群，如自然杀伤（NK）细胞、ILC1、ILC2、ILC3以及淋巴组织诱导（LTi）细胞，它们表达的受体和信号通路对不断变化的微环境信号高度敏感。在本综述中，我们重点介绍固有细胞的关键特征，这些特征决定了它们快速响应不同环境的能力，以及这种能力如何既能驱动肿瘤保护（限制肿瘤发展），又能促进肿瘤进展，推动肿瘤播散和免疫治疗耐药。我们讨论了理解能够在应答早期检测肿瘤细胞的ILC调控机制，如何为利用这种功能可塑性来开发合理的治疗策略提供了可能，从而增强适应性免疫应答并改善患者预后。
展开英文摘要原文
Innate lymphoid cells (ILCs) comprise a number of different subsets, including natural killer (NK) cells, ILC1s, ILC2s, ILC3s, and lymphoid tissue-inducer (LTi) cells that express receptors and signaling pathways that are highly responsive to continuously changing microenvironmental cues.
In this Review, we highlight the key features of innate cells that define their capacity to respond rapidly to different environments, how this ability can drive both tumor protection (limiting tumor development) or, alternatively, tumor progression, promoting tumor dissemination and resistance to immunotherapy.
We discuss how understanding the regulation of ILCs that can detect tumor cells early in a response opens the possibility of exploiting this functional plasticity to develop rational therapeutic strategies to bolster adaptive immune responses and improve patient outcomes.
论文信息
- 作者
- Ng CK、Belz GT
- 第一作者单位
- The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD 4102, Australia.Australia
- 通讯作者单位
- The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD 4102, Australia. Electronic address: g.belz@uq.edu.au.Australia
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Trends in cancer2023 Feb
- 原文标识
- PubMed 36357314 · DOI 10.1016/j.trecan.2022.10.007